IL275348B2 - Carbamoyl cyclohexyl acids linked via n triazole as lpa antagonists - Google Patents
Carbamoyl cyclohexyl acids linked via n triazole as lpa antagonistsInfo
- Publication number
- IL275348B2 IL275348B2 IL275348A IL27534820A IL275348B2 IL 275348 B2 IL275348 B2 IL 275348B2 IL 275348 A IL275348 A IL 275348A IL 27534820 A IL27534820 A IL 27534820A IL 275348 B2 IL275348 B2 IL 275348B2
- Authority
- IL
- Israel
- Prior art keywords
- alkyl
- compound according
- haloalkyl
- cycloalkyl
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C249/04—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes
- C07C249/06—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by nitrosation of hydrocarbons or substituted hydrocarbons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/04—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762607399P | 2017-12-19 | 2017-12-19 | |
| PCT/US2018/066117 WO2019126090A1 (en) | 2017-12-19 | 2018-12-18 | Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL275348A IL275348A (en) | 2020-07-30 |
| IL275348B1 IL275348B1 (en) | 2023-04-01 |
| IL275348B2 true IL275348B2 (en) | 2023-08-01 |
Family
ID=65003579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL275348A IL275348B2 (en) | 2017-12-19 | 2020-06-14 | Carbamoyl cyclohexyl acids linked via n triazole as lpa antagonists |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US10662172B2 (enExample) |
| EP (2) | EP3710438B1 (enExample) |
| JP (1) | JP7274486B6 (enExample) |
| KR (1) | KR102702229B1 (enExample) |
| CN (2) | CN112521368B (enExample) |
| AR (1) | AR113964A1 (enExample) |
| AU (1) | AU2018392321B2 (enExample) |
| CA (1) | CA3085586C (enExample) |
| CL (1) | CL2020001547A1 (enExample) |
| CY (1) | CY1124863T1 (enExample) |
| DK (1) | DK3710438T3 (enExample) |
| EA (1) | EA202091506A1 (enExample) |
| ES (1) | ES2898364T3 (enExample) |
| HR (1) | HRP20211918T8 (enExample) |
| HU (1) | HUE057366T2 (enExample) |
| IL (1) | IL275348B2 (enExample) |
| LT (1) | LT3710438T (enExample) |
| MX (1) | MX394467B (enExample) |
| MY (1) | MY199103A (enExample) |
| NZ (1) | NZ766284A (enExample) |
| PE (1) | PE20210655A1 (enExample) |
| PL (1) | PL3710438T3 (enExample) |
| PT (1) | PT3710438T (enExample) |
| RS (1) | RS62710B1 (enExample) |
| SG (1) | SG11202005699QA (enExample) |
| SI (1) | SI3710438T1 (enExample) |
| SM (1) | SMT202100716T1 (enExample) |
| TW (1) | TWI830713B (enExample) |
| WO (1) | WO2019126090A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| WO2019126084A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Isoxazole o-linked carbamoyl cyclohexyl acids as lpa antagonists |
| EP3728222B1 (en) | 2017-12-19 | 2023-03-29 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azines as lpa antagonists |
| US11447475B2 (en) | 2017-12-19 | 2022-09-20 | Bristol-Myers Squibb Company | Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists |
| WO2019126094A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid triazole azoles as lpa antagonists |
| EA202091500A1 (ru) | 2017-12-19 | 2020-09-14 | Бристол-Маерс Сквибб Компани | Пиразол n-связанные карбамоилциклогексильные кислоты в качестве антагонистов lpa |
| WO2019126087A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azoles as lpa antagonists |
| AR113964A1 (es) | 2017-12-19 | 2020-07-01 | Bristol Myers Squibb Co | Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa |
| WO2019126086A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azines as lpa antagonists |
| CA3085561A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid triazole azines as lpa antagonists |
| KR102726939B1 (ko) | 2017-12-19 | 2024-11-05 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로헥실 산 피라졸 아졸 |
| CN112041302B (zh) | 2017-12-19 | 2024-11-19 | 百时美施贵宝公司 | 作为lpa拮抗剂的吡唑o-连接的氨基甲酰基环己基酸 |
| HUE060711T2 (hu) | 2017-12-19 | 2023-04-28 | Turning Point Therapeutics Inc | Makrociklusos vegyületek betegségek kezelésére |
| US12428430B2 (en) | 2018-09-18 | 2025-09-30 | Bristol-Myers Squibb Company | Oxabicyclo acids as LPA antagonists |
| KR20210061383A (ko) | 2018-09-18 | 2021-05-27 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로펜틸 산 |
| JP7367038B2 (ja) * | 2018-10-15 | 2023-10-23 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａ１受容体のイメージングのための放射性リガンド |
| CN111434653A (zh) * | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 三氮唑类化合物及其制备方法与用途 |
| KR20220039718A (ko) | 2019-07-30 | 2022-03-29 | 다이쇼 세이야꾸 가부시끼가이샤 | Lpa1 수용체를 길항하는 우레아 화합물 |
| CN110590599B (zh) * | 2019-09-30 | 2022-07-26 | 大连民族大学 | 一种群体感应信号分子结构类似物及其制备方法 |
| CN114728168B (zh) | 2019-11-15 | 2024-04-09 | 吉利德科学公司 | 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途 |
| CN114786771A (zh) | 2019-12-12 | 2022-07-22 | 奇斯药制品公司 | 作为lpa受体2抑制剂的喹唑啉衍生物 |
| EP4073069B1 (en) | 2019-12-12 | 2023-12-06 | Chiesi Farmaceutici S.p.A. | Aromatic amido derivatives as lpa receptor 2 inhibitors |
| EP4073073B1 (en) | 2019-12-12 | 2023-12-06 | Chiesi Farmaceutici S.p.A. | Thienopyrimidine derivatives as lpa receptor 2 inhibitors |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| EP4161936A1 (en) | 2020-06-03 | 2023-04-12 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| CN115989220A (zh) | 2020-07-16 | 2023-04-18 | 奇斯药制品公司 | 作为lpa受体抑制剂的酰氨基环己烷酸衍生物 |
| CN114456159A (zh) * | 2020-11-10 | 2022-05-10 | 武汉人福创新药物研发中心有限公司 | 氮取代杂环噻吩类化合物及其用途 |
| WO2022115049A1 (en) | 2020-11-25 | 2022-06-02 | Yeditepe Universitesi | Molecular basis of fatty liver inhibition by sodium borates |
| WO2022174883A1 (en) | 2021-02-16 | 2022-08-25 | Chiesi Farmaceutici S.P.A. | 5-membered heterocyclyl derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors |
| WO2022174882A1 (en) | 2021-02-16 | 2022-08-25 | Chiesi Farmaceutici S.P.A. | 5-membered heterocyclyl carbamate derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors |
| WO2022199815A1 (en) | 2021-03-24 | 2022-09-29 | Chiesi Farmaceutici S.P.A. | 8-cyclo-substituted quinazoline derivatives as lpa receptor 2 inhibitors |
| EP4337641A1 (en) | 2021-05-11 | 2024-03-20 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| JP7691522B2 (ja) * | 2021-05-13 | 2025-06-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｌｐａ受容体アンタゴニスト及びそれらの使用 |
| EP4444707A1 (en) | 2021-12-08 | 2024-10-16 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| WO2023118253A1 (en) | 2021-12-23 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Cyclohexane acid derivatives as lpa receptor inhibitors |
| US20250188068A1 (en) | 2022-03-08 | 2025-06-12 | Chiesi Farmaceutici S.P.A. | Amido cyclopropyl derivatives as lpa receptor inhibitors |
| WO2025051267A1 (zh) * | 2023-09-08 | 2025-03-13 | 西藏海思科制药有限公司 | 一种lpar1拮抗剂及其用途 |
| WO2025051266A1 (zh) * | 2023-09-08 | 2025-03-13 | 西藏海思科制药有限公司 | 杂芳环衍生物的lpar1拮抗剂及其用途 |
| WO2025162421A1 (zh) * | 2024-02-04 | 2025-08-07 | 西藏海思科制药有限公司 | Lpar1拮抗剂及其用途 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012138648A1 (en) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| WO2013189864A1 (en) * | 2012-06-20 | 2013-12-27 | F. Hoffmann-La Roche Ag | N-alkyltriazole compounds as lpar antagonists |
| WO2017223016A1 (en) * | 2016-06-21 | 2017-12-28 | Bristol-Myers Squibb Company | Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001060819A1 (en) | 2000-02-18 | 2001-08-23 | Kirin Beer Kabushiki Kaisha | Novel isoxazole and thiazole compounds and use thereof as drugs |
| DE60234318D1 (de) | 2001-02-08 | 2009-12-24 | Ono Pharmaceutical Co | Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors |
| WO2005012269A1 (ja) | 2003-08-05 | 2005-02-10 | Ajinomoto Co., Inc. | 新規アゾール化合物 |
| US7432271B2 (en) | 2003-09-02 | 2008-10-07 | Bristol-Myers Squibb Company | Pyrazolyl inhibitors of 15-lipoxygenase |
| DE102004038403B4 (de) | 2004-08-07 | 2006-08-31 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten |
| US20080186971A1 (en) | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| GB0806794D0 (en) | 2008-04-15 | 2008-05-14 | Ludwig Inst Cancer Res | Therapeutic compounds |
| EP2462128B1 (en) | 2009-08-04 | 2016-09-21 | Amira Pharmaceuticals, Inc. | Compounds as lysophosphatidic acid receptor antagonists |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| US8742097B2 (en) | 2010-11-09 | 2014-06-03 | Hoffmann-La Roche Inc. | Triazole compounds I |
| CN103443098B (zh) | 2011-01-30 | 2016-03-16 | 广州源生医药科技有限公司 | 作为溶血磷脂酸受体的拮抗剂的化合物、组合物及其应用 |
| JP5976011B2 (ja) | 2011-04-05 | 2016-08-23 | 武田薬品工業株式会社 | スルホンアミド誘導体およびその用途 |
| WO2013070879A1 (en) | 2011-11-10 | 2013-05-16 | Bristol-Myers Squibb Company | Methods for treating spinal cord injury with lpa receptor antagonists |
| WO2013085824A1 (en) | 2011-12-04 | 2013-06-13 | Angion Biomedica Corp. | Small molecule anti-fibrotic compounds and uses thereof |
| TW201437200A (zh) * | 2013-01-15 | 2014-10-01 | Intermune Inc | 溶血磷脂酸受體拮抗劑 |
| CN105142635B (zh) | 2013-03-15 | 2021-07-27 | 艾匹根生物技术有限公司 | 有用于治疗疾病的杂环化合物 |
| WO2016044556A2 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| JP6853619B2 (ja) * | 2015-01-16 | 2021-03-31 | 大塚製薬株式会社 | シアノトリアゾール化合物の医薬用途 |
| WO2019126086A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azines as lpa antagonists |
| WO2019126087A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azoles as lpa antagonists |
| HUE060711T2 (hu) | 2017-12-19 | 2023-04-28 | Turning Point Therapeutics Inc | Makrociklusos vegyületek betegségek kezelésére |
| CA3085561A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid triazole azines as lpa antagonists |
| KR102726939B1 (ko) | 2017-12-19 | 2024-11-05 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로헥실 산 피라졸 아졸 |
| WO2019126084A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Isoxazole o-linked carbamoyl cyclohexyl acids as lpa antagonists |
| CN112041302B (zh) | 2017-12-19 | 2024-11-19 | 百时美施贵宝公司 | 作为lpa拮抗剂的吡唑o-连接的氨基甲酰基环己基酸 |
| AR113964A1 (es) | 2017-12-19 | 2020-07-01 | Bristol Myers Squibb Co | Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa |
| US11447475B2 (en) | 2017-12-19 | 2022-09-20 | Bristol-Myers Squibb Company | Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists |
| WO2019126094A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid triazole azoles as lpa antagonists |
| EP3728222B1 (en) | 2017-12-19 | 2023-03-29 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azines as lpa antagonists |
| EA202091500A1 (ru) | 2017-12-19 | 2020-09-14 | Бристол-Маерс Сквибб Компани | Пиразол n-связанные карбамоилциклогексильные кислоты в качестве антагонистов lpa |
-
2018
- 2018-12-18 AR ARP180103700A patent/AR113964A1/es unknown
- 2018-12-18 DK DK18830680.7T patent/DK3710438T3/da active
- 2018-12-18 SI SI201830475T patent/SI3710438T1/sl unknown
- 2018-12-18 CN CN202011353094.2A patent/CN112521368B/zh active Active
- 2018-12-18 EP EP18830680.7A patent/EP3710438B1/en active Active
- 2018-12-18 JP JP2020533840A patent/JP7274486B6/ja active Active
- 2018-12-18 RS RS20211542A patent/RS62710B1/sr unknown
- 2018-12-18 PT PT188306807T patent/PT3710438T/pt unknown
- 2018-12-18 KR KR1020207020553A patent/KR102702229B1/ko active Active
- 2018-12-18 CN CN201880080910.1A patent/CN112189010A/zh active Pending
- 2018-12-18 ES ES18830680T patent/ES2898364T3/es active Active
- 2018-12-18 PE PE2020000746A patent/PE20210655A1/es unknown
- 2018-12-18 EA EA202091506A patent/EA202091506A1/ru unknown
- 2018-12-18 MX MX2020006315A patent/MX394467B/es unknown
- 2018-12-18 HR HRP20211918TT patent/HRP20211918T8/hr unknown
- 2018-12-18 CA CA3085586A patent/CA3085586C/en active Active
- 2018-12-18 TW TW107145551A patent/TWI830713B/zh not_active IP Right Cessation
- 2018-12-18 NZ NZ766284A patent/NZ766284A/en not_active IP Right Cessation
- 2018-12-18 HU HUE18830680A patent/HUE057366T2/hu unknown
- 2018-12-18 MY MYPI2020003100A patent/MY199103A/en unknown
- 2018-12-18 WO PCT/US2018/066117 patent/WO2019126090A1/en not_active Ceased
- 2018-12-18 SG SG11202005699QA patent/SG11202005699QA/en unknown
- 2018-12-18 EP EP21203235.3A patent/EP4011875A1/en not_active Withdrawn
- 2018-12-18 US US16/223,169 patent/US10662172B2/en active Active
- 2018-12-18 PL PL18830680T patent/PL3710438T3/pl unknown
- 2018-12-18 LT LTEPPCT/US2018/066117T patent/LT3710438T/lt unknown
- 2018-12-18 SM SM20210716T patent/SMT202100716T1/it unknown
- 2018-12-18 AU AU2018392321A patent/AU2018392321B2/en active Active
-
2020
- 2020-01-16 US US16/744,303 patent/US11008300B2/en active Active
- 2020-06-10 CL CL2020001547A patent/CL2020001547A1/es unknown
- 2020-06-14 IL IL275348A patent/IL275348B2/en unknown
-
2021
- 2021-04-07 US US17/224,161 patent/US11697646B2/en active Active
- 2021-12-14 CY CY20211101119T patent/CY1124863T1/el unknown
-
2023
- 2023-05-22 US US18/321,092 patent/US12195444B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012138648A1 (en) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| WO2013189864A1 (en) * | 2012-06-20 | 2013-12-27 | F. Hoffmann-La Roche Ag | N-alkyltriazole compounds as lpar antagonists |
| WO2017223016A1 (en) * | 2016-06-21 | 2017-12-28 | Bristol-Myers Squibb Company | Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275348B2 (en) | Carbamoyl cyclohexyl acids linked via n triazole as lpa antagonists | |
| JP2021508686A5 (enExample) | ||
| ES2628953T3 (es) | Sulfamoilarilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis B | |
| DE602004010708T2 (de) | Imidazopyridinsubstituierte tropanderivate mit ccr5-rezeptorantagonistischer wirkung zur behandlung von hiv und entzündungen | |
| JP2019518766A5 (enExample) | ||
| US20090124636A1 (en) | Chemical compounds | |
| AU2019207611A1 (en) | Benzamide compounds | |
| JP2021507900A5 (enExample) | ||
| UA118989C2 (uk) | Дигідропіролопіридинові інгібітори ror-гамма | |
| JPWO2019126099A5 (enExample) | ||
| JP6783756B2 (ja) | ｍＩＤＨ１阻害剤としてのベンゾイミダゾール−２−アミン | |
| JPWO2019126086A5 (enExample) | ||
| JP2016519659A5 (enExample) | ||
| AU2019362770A1 (en) | Radioligands for imaging the LPA1 receptor | |
| JP2021502358A5 (enExample) | ||
| JP2014502599A5 (enExample) | ||
| JPWO2020060915A5 (enExample) | ||
| JPWO2019126085A5 (enExample) | ||
| JP2024033009A (ja) | インフルエンザを処置するためのオルソミクソウイルス複製の阻害剤としての１０－（ジ（フェニル）メチル）－４－ヒドロキシ－８，９，９ａ，１０－テトラヒドロ－７Ｈ－ピロロ［１’，２’：４，５］ピラジノ［１，２－ｂ］ピリダジン－３，５－ジオン誘導体および関連化合物 | |
| RU2009145296A (ru) | Бициклосульфониловая кислота (bcsa) и ее применение в качестве терапевтического агента | |
| JP2017535566A5 (enExample) | ||
| JPWO2020060914A5 (enExample) | ||
| CA2856824A1 (en) | Cyclic urea derivatives as androgen receptor antagonists | |
| JPWO2020060916A5 (enExample) | ||
| CN115551846B (zh) | 1,4,5,6-四氢嘧啶-2-胺衍生物 |